Tegmine Therapeutics

Website
4104 24th St
San Francisco, CA 94114

Tegmine Therapeutics, based in San Francisco, specializes in the development of innovative antibody-based therapies aimed at targeting glycoproteins associated with various solid cancers. Their proprietary TegMiner platform facilitates the discovery of unique cancer epitopes, enabling the creation of advanced treatment options that enhance efficacy while minimizing side effects for patients with unmet medical needs.

The leadership team, including CEO Jeff Bernstein and CTO Daniel Hyduke, brings extensive experience in biomedical engineering and computational biology, having worked on numerous cancer-related projects and contributing significantly to the scientific community. With a commitment to eradicating cancer, Tegmine aims to revolutionize treatment options and improve patient outcomes through their cutting-edge research and development initiatives.

Generated from the website

Own this business?
See a problem?

You might also like

United StatesCaliforniaSan FranciscoTegmine Therapeutics